EXTON, Pa., July 28 /PRNewswire/ -- BioTrends Research Group, Inc. recently released its baseline report assessing awareness of the Centers for Medicare and Medicaid Services (CMS) proposed dialysis bundled payment plan among Medical Directors and Renal Administrators in dialysis units across the country. Approximately half of the respondents were affiliated with large dialysis chains (i.e. Fresenius, DaVita, DCI) with the other half operating in small-to-medium sized dialysis chains, independent units, and hospital based units.
The report, based on survey responses from 160 Medical Directors and 117 Renal Administrators and supplemented with qualitative interviews conducted with key stakeholders (dialysis organization executives, renal organizations, key opinion leaders on the subject of bundling), examines awareness of the proposed bundle components, anticipated changes in practice management, the degree of control in decision making Medical Directors and Renal Administrators expect to have, and their overall concerns with bundle implementation. Specific impact on the utilization of ESAs, IV iron, Vitamin D, phosphate binders, and Amgen's Sensipar is explored as it relates to how likely various scenarios are and whether or not they are in the best interest of dialysis patients.
Although exact details of the bundled payment system have yet to be finalized and made official, Medical Directors and Renal Administrators are clearly concerned about the impact of these changes on the fiscal health (and viability) of their units as well as the potential impact on patient outcomes. The most valuable sources of information on bundling were noted as the Renal Physician's Association for Medical Directors and the ESRD Networks for Renal Administrators.
The full report is available for purchase at www.bio-trends.com. A follow up wave of
|SOURCE BioTrends Research Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved